A Phase 2 interventional study of GRT6005 and GRT6005 in Pain and Diabetic Neuropathies, sponsored by Tris Pharma, Inc.. Completed at 22 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-15.
Sponsored by Tris Pharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 201 studies in Pain with a site in Germany — 13 open to participants now, 14 under way, 8 of them phase 3. Pain · Germany.
Among the 201 studies in Pain with a site in Germany, this one is the 54th largest by enrollment of the 162 interventional ones that give a count, is one of 21 that started in 2011, is one of 26 in phase 2, and was the 83rd registered.
10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.
Browse Pain studies →13 of the 201 studies in Pain with a site in Germany are open now. Recruiting first, the newest first:
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) · Sites in Germany
Ages 18–99 · Women only
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
201 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 33 · Phase 3 50 · Phase 4 13
First in 2001; this study’s year is marked. 21 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 189 is above the median of 66 across 8,502 interventional studies indexed under Pain.
Median enrollment 111 across the 162 interventional studies, 100 across the 39 observational. Of the 169 that completed or were terminated, 49 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
95 of 201 have an industry lead sponsor. The 10 most frequent:
Tris Pharma, Inc. is the lead sponsor of 22 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 4 (31%) have results posted.
Tris Pharma, Inc. has 7 studies filed under Pain — fewer than ten, so there is no comparison to draw.
2 of the studies in Pain with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07423039Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)Auricular Acupressure for Perioperative Anxiety and Pain in Therapeutic Breast Surgery (ROSA) | 2027-06-30 |
| NCT05867186Johannes Gutenberg University MainzFit to Fight Childhood Cancer | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 201 studies in Pain with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to investigate the efficacy and safety of GRT6005 in patients with painful diabetic neuropathy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants allocated to this treatment arm will receive a daily dose of 25 µg GRT6005 per day
Drug: GRT6005
Participants allocated to this treatment arm will receive a daily dose of 75 µg GRT6005 per day
Drug: GRT6005
Participants allocated to this treatment arm will receive a daily dose of 200 µg GRT6005 per day
Drug: GRT6005
Participants allocated to this treatment arm will receive a dose of matched placebo once a day.
Drug: Matching Placebo
Change in mean daily pain intensity score
Participants will be selected based on their medical history and clinical examination. Efficacy of the treatment (i.e., reduction of pain) will be evaluated with the 11-point numeric rating scale (NRS), where 0 represents no pain and 10 represents "pain as bad as you can imagine".
Time frame: Baseline to Week 4
Response measured in percentage change of pain intensity from baseline
Time frame: End of 4 Weeks
Changes in Quantitative Sensory Testing from baseline
Time frame: Baseline, week 1 and week 4
Neuropathic Pain Scale, changes from baseline
Time frame: End of 4 weeks
Short Form of the Brief Pain Inventory, changes from baseline
Time frame: End of 4 weeks
Leeds Sleep Evaluation Questionnaire
Time frame: End of treatment
Quality of Life Index -Short-Form-12®, from baseline
Time frame: End of treatment
Patient's Global Impression of Change
Time frame: End of treatment
Quality of Life EuroQoL-5 Dimension score, change from baseline
Time frame: End of 4 weeks
Rescue medication use
Time frame: End of 4 weeks
Clinical Opioid Withdrawal Scale
Time frame: End of 4 weeks
Plasma concentration
Time frame: End of 4 weeks
The record gives a start of May 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cebranopadol